Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available. In an interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, ...
Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
BioTraceIO360 received FDA 510(k) clearance for kidney ablation, expanding its previous liver tumor ablation indication. The platform standardizes minimally invasive care, enhancing treatment planning ...
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...
FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for solid tumors in patients 12 years and older. Recommended dosages are 395 mg/4800 units every 3 weeks or 790 mg/9600 units ...
Combining BCG with ICIs targets the PD-1/PD-L1 pathway to overcome BCG resistance in NMIBC. The CREST trial showed improved event-free survival with BCG plus sasanlimab compared to BCG alone. Future ...
Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...
The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...
Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...
Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...
Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback